Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis

Fabrizio Ayala, N. Balato, F. Gaudiello, Fabio Ayala

Research output: Contribution to journalArticle

Abstract

Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalGiornale Italiano di Dermatologia e Venereologia
Volume142
Issue number1
Publication statusPublished - 2007

Fingerprint

Atopic Dermatitis
Safety
Histamine H1 Receptors
Pruritus
Signs and Symptoms
Anti-Inflammatory Agents
desloratadine
Therapeutics
Pharmaceutical Preparations

Keywords

  • Dermatitis, atopic
  • Desloratadine
  • Histamine H1 antagonists

ASJC Scopus subject areas

  • Dermatology

Cite this

Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis. / Ayala, Fabrizio; Balato, N.; Gaudiello, F.; Ayala, Fabio.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 142, No. 1, 2007, p. 29-34.

Research output: Contribution to journalArticle

@article{7f0cc62a770245cd907d7941f2a5e0c2,
title = "Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis",
abstract = "Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5{\%}, marked relief in 70{\%}, moderate relief in 15{\%} and slight relief in 2.5{\%} of the patients. Thirty-three children (82.5{\%}) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5{\%} of children showed adverse events.",
keywords = "Dermatitis, atopic, Desloratadine, Histamine H1 antagonists",
author = "Fabrizio Ayala and N. Balato and F. Gaudiello and Fabio Ayala",
year = "2007",
language = "English",
volume = "142",
pages = "29--34",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Evaluation of efficacy and safety of desloratadine syrup in childhood atopic dermatitis

AU - Ayala, Fabrizio

AU - Balato, N.

AU - Gaudiello, F.

AU - Ayala, Fabio

PY - 2007

Y1 - 2007

N2 - Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.

AB - Aim. The aim of this study is to evaluate the efficacy, safety and adverse effects of desloratadine (DL), a H1-receptor antagonist, as syrup in children with atopic dermatitis (AD). Methods. Forty patients aged between 6 and 12 years were selected from a sample of children with AD referred to our institute from April to July 2003; DL syrup was administered once daily (5 mL - 2.5 mg) for 28 days. We evaluated the efficacy of treatment by SCORAD index and the possible adverse events at day 8, 15 and 29. Results. As for the global therapeutic response we observed complete relief in 12.5%, marked relief in 70%, moderate relief in 15% and slight relief in 2.5% of the patients. Thirty-three children (82.5%) did not show any adverse event. Conclusion. DL syrup is a valid treatment of AD in children. We observed a reduction of signs and symptoms that characterize AD, due to anti-itching and anti-inflammatory activity of DL. This is also a good tolerated drug, as only 17.5% of children showed adverse events.

KW - Dermatitis, atopic

KW - Desloratadine

KW - Histamine H1 antagonists

UR - http://www.scopus.com/inward/record.url?scp=34247281102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247281102&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34247281102

VL - 142

SP - 29

EP - 34

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 1

ER -